Table.
Demographic and Clinical Characteristics at the Baseline Visit
| Variable | Cohort | |
| PPMI cohort (N = 417) | Penn cohort (N = 389) | |
| Age at baseline visit, y | ||
| Mean (SD) | 61.6 (9.8) | 69.3 (8.0) |
| Min, max | 33, 85 | 49, 94 |
| PD duration at baseline visit, y | ||
| Mean (SD) | 0.6 (0.5) | 6.3 (5.3) |
| Min, max | 0, 3 | 0, 32 |
| Age at PD diagnosis categories, n (%) | ||
| Age <56 | 138 (33) | 89 (23) |
| Age 56–70 | 212 (51) | 213 (55) |
| Age >70 | 59 (14) | 87 (22) |
| Missing | 8 (2) | 0 |
| Sex, n (%) | ||
| Male | 272 (65) | 261 (67) |
| Female | 145 (35) | 128 (33) |
| Race, n (%) | ||
| White | 385 (92) | 362 (93) |
| Non-White | 29 (7) | 27 (7) |
| Missing | 3 (1) | 0 |
| Education, y | ||
| Mean (SD) | 15.6 (3.0) | 16.0 (2.5) |
| Min, max | 5, 26 | 8, 21 |
| MDS-UPDRS III total score | ||
| Mean (SD) | 20.9 (8.9) | 28.2 (13.2)a |
| Min, max | 4, 51 | 2, 85 |
| Missing | 0 | 6 |
| Hoehn and Yahr, n (%) | ||
| 1 | 183 (44) | 33 (8) |
| 2 | 232 (56) | 151 (39) |
| 3 | 2 (<1) | 185 (48) |
| 4/5 | 0 | 16 (4) |
| Missing | 0 | 4 (1) |
| MoCA | ||
| Median | 28 | 26 |
| Min, max | 17, 30 | 7, 30 |
| Missing | 0 | 215b |
| LEDD | ||
| Median | NA | 600 |
| Min, max | NA | 0, 2,960 |
Abbreviations: LEDD = levodopa equivalent daily dose; MDS-UPDRS III = Movement Disorder Society—Unified Parkinson's Disease Rating Scale part III; MoCA = Montreal Cognitive Assessment; NA = not available; PD = Parkinson disease; Penn = University of Pennsylvania; PPMI = Parkinson's Progression Markers Initiative.
a
UPDRS III score converted to MDS-UPDRS III score for the Penn cohort.41
b
MoCA score not administered at the baseline visit for the Penn cohort for original participants.